anuscript Number: INFOH-D-24-00067  

# Large Language Models Driven Reliable Clinical Decision-Making: Framework and Application

[大语言模型驱动的可靠临床决策：框架与应用]

Dear Professor Liu,    
[刘教授：]

Thank you for submitting your manuscript to Informatics and Health.
[感谢您向《信息学与健康》期刊投稿。]

I have completed my evaluation of your manuscript. The reviewers recommend reconsideration of your manuscript following revision. I invite you to resubmit your manuscript after addressing the comments below. Please resubmit your revised manuscript by Apr 15, 2025.
[我已经完成了对您稿件的评估。审稿人建议在修改后重新考虑您的稿件。我邀请您在解决以下意见后重新提交稿件。请在2025年4月15日之前重新提交修改后的稿件。]
 
When revising your manuscript, please consider all issues mentioned in the reviewers' comments carefully: please outline in a cover letter every change made in response to their comments and provide suitable rebuttals for any comments not addressed. Please note that your revised submission may need to be re-reviewed.     
[在修改稿件时，请仔细考虑审稿人意见中提到的所有问题：请在附信中概述针对他们意见所做的每一项修改，并对未处理的意见提供适当的反驳。请注意，您的修改后提交可能需要重新审阅。]

To submit your revised manuscript, please log in as an author at [https://www.editorialmanager.com/infoh/,](https://www.editorialmanager.com/infoh/, "https://www.editorialmanager.com/infoh/,") and navigate to the "Submissions Needing Revision" folder under the Author Main Menu.
[要提交修改后的稿件，请以作者身份登录[https://www.editorialmanager.com/infoh/,](https://www.editorialmanager.com/infoh/, "https://www.editorialmanager.com/infoh/,")，并在作者主菜单下导航到"需要修改的提交"文件夹。]

Research Elements (optional)
[研究要素（可选）]
This journal encourages you to share research objects - including your raw data, methods, protocols, software, hardware and more – which support your original research article in a Research Elements journal. Research Elements are open access, multidisciplinary, peer-reviewed journals which make the objects associated with your research more discoverable, trustworthy and promote replicability and reproducibility. As open access journals, there may be an Article Publishing Charge if your paper is accepted for publication. Find out more about the Research Elements journals at [https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email.](https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email. "https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email.")
[本期刊鼓励您在研究要素期刊上分享研究对象 - 包括您的原始数据、方法、协议、软件、硬件等 - 这些内容支持您的研究文章。研究要素是开放获取、多学科、同行评议的期刊，使与您的研究相关的对象更容易被发现、更值得信赖，并促进可重复性和可再现性。作为开放获取期刊，如果您的论文被接受发表，可能需要支付文章出版费。在[https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email.](https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email. "https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email.")了解更多关于研究要素期刊的信息。]

Informatics and Health values your contribution and I look forward to receiving your revised manuscript.
[《信息学与健康》重视您的贡献，我期待收到您修改后的稿件。]
 
Kind regards,    
[此致，]
Chen Wang  
Editor-in-Chief  
Informatics and Health    
[王晨
主编
《信息学与健康》]

Editor and Reviewer Comments:    
[编辑和审稿人意见：]

 
 
Reviewer 2:
[审稿人2：]
Generally, the manuscript is well written however, it should be revised as the following:
[总的来说，稿件写得很好，但需要按以下方式进行修改：]

- The paper tackles a crucial challenge in the application of LLMs in healthcare: the need for reliable and stable clinical decision-making. The importance of this issue is well-established, and the proposed framework directly addresses it.
  [本文探讨了LLM在医疗保健应用中的一个关键挑战：需要可靠和稳定的临床决策。这个问题的重要性已经得到充分证实，所提出的框架直接解决了这个问题。]
- While the framework is described, the paper lacks detailed information about the specific implementation of each component. For example, the type of knowledge engineering used, the architecture of the intelligent agents, and the fine-tuning process of the LLMs are not thoroughly explained. This lack of detail hinders reproducibility and evaluation.
  [虽然描述了框架，但论文缺乏关于每个组件的具体实现的详细信息。例如，使用的知识工程类型、智能代理的架构以及LLM的微调过程都没有得到充分解释。这种细节的缺乏阻碍了可重复性和评估。]
- Include specific details about the implementation of each component of the MedRad framework, including the algorithms used, the datasets employed, and the evaluation metrics applied.
  -Perform comprehensive experiments using standard datasets and evaluation metrics to validate the effectiveness of MedRad. Include both quantitative and qualitative analyses.
  [包括MedRad框架每个组件的具体实现细节，包括使用的算法、采用的数据集和应用的评估指标。使用标准数据集和评估指标进行全面的实验，以验证MedRad的有效性。包括定量和定性分析。]

  All figures and tables in a paper must be consistent. Please make sure all figures are high-resolution (300 dpi).
  [论文中的所有图表必须保持一致。请确保所有图片都是高分辨率（300 dpi）。]

  -The paper should be enriched with references to existing research papers on to High Performance Medicine: Involving Artificial Intelligence Models in Enhancing Medical Laws and Medical Negligence Matters A Case Study of Act, 2009 (Act 792) in Ghana such as [https://doi.org/10.70470/SHIFAA/2025/001](https://doi.org/10.70470/SHIFAA/2025/001 "https://doi.org/10.70470/SHIFAA/2025/001") This would strengthen the argument and provide readers with additional resources for further exploration.
  [论文应该增加对现有研究论文的引用，如关于高性能医学：人工智能模型在加强医疗法律和医疗过失事项中的应用 - 2009年加纳法案（第792号）的案例研究，如[https://doi.org/10.70470/SHIFAA/2025/001](https://doi.org/10.70470/SHIFAA/2025/001 "https://doi.org/10.70470/SHIFAA/2025/001")。这将加强论点并为读者提供额外的资源以供进一步探索。]

  -To enhance the paper's impact, the author should discuss potential future directions for this research.
  [为了增强论文的影响力，作者应该讨论这项研究的潜在未来方向。]

Reviewer 3: The authors propose a very important research question to accomplish credible clinical decision support using LLM. The framework of MedRad is presented, but it has no substantial innovative content, being two block diagrams with no specific and reproducible technical route. The specific scenarios used for evaluation lack details, such as what are the topics used for testing? How many? How is the quantitative precision for QA calculated? Typically, QA is evaluated on a variety of scores, such as ROUGE-1, ROUGE-2, and ROUGE-L scores, and there is a lack of description of the qualitative evaluation, what are the clinical questions? What kind of evaluation criteria? Therefore, it is not possible to evaluate whether the effect of the study is reliable or not, and it lacks some basic elements of scientific research.
[审稿人3：作者提出了一个非常重要的问题，即使用LLM实现可靠的临床决策支持。虽然提出了MedRad框架，但它没有实质性的创新内容，只是两个没有具体和可重复技术路线的框图。用于评估的具体场景缺乏细节，例如使用了哪些测试主题？数量是多少？QA的定量精度是如何计算的？通常，QA是通过各种分数来评估的，如ROUGE-1、ROUGE-2和ROUGE-L分数，而且缺乏定性评估的描述，临床问题是什么？评估标准是什么？因此，无法评估研究的效果是否可靠，并且缺乏科学研究的一些基本要素。]

If given the opportunity it could be enhanced in the following ways:

1. description of technical details. For example, the data in Table 1 are used in the training of which models, how they are trained, and the difference between before and after training. the specific implementation techniques of the RAG in Figure2. How is a problem split into different options? Clinical diagnosis recommendation is supposed to be oriented to the patient's main complaint, so the clinical decision-making scenario is relatively homogeneous and cannot represent diverse clinical scenarios.
   [1. 技术细节的描述。例如，表1中的数据用于哪些模型的训练，如何训练，以及训练前后的差异。图2中RAG的具体实现技术。问题是如何分解为不同选项的？临床诊断建议应该以患者的主诉为导向，因此临床决策场景相对单一，不能代表多样化的临床场景。]
2. Openness and fairness of the assessment method. There is a need to show in detail what is used in the assessment as well as the indicators used in the assessment. Especially for the qualitative part of the indicators, how do the 20 clinicians work and what is the Agreement rate between different assessors?
   [2. 评估方法的开放性和公平性。需要详细说明评估中使用了什么以及使用的指标。特别是对于指标的定性部分，20位临床医生是如何工作的，不同评估者之间的同意率是多少？]

Reviewer 4: Thank you for the opportunity to review the manuscript titled "Large Language Models Driven Reliable Clinical Decision-Making: Framework and Application." However, the manuscript appears to be incomplete and not yet ready for submission. The results section lacks essential details. For example, data values in Table 1 were missing. Additionally, the discussion is underdeveloped, consisting of only a single paragraph that provides a superficial summary without meaningful analysis or interpretation of the findings. I encourage the authors to complete this work and resubmit the manuscript.
[审稿人4：感谢您让我有机会审阅题为"大语言模型驱动的可靠临床决策：框架与应用"的稿件。然而，稿件似乎不完整，尚未准备好提交。结果部分缺乏必要的细节。例如，表1中的数据值缺失。此外，讨论部分发展不足，仅包含一个段落，提供了表面的总结，没有对发现进行有意义的分析或解释。我鼓励作者完成这项工作并重新提交稿件。]

Another major concern is the lack of representation and generalizability of the proposed framework and its application. Evaluating only two scenarios is insufficient to demonstrate the robustness of the MedRad model. The authors emphasize the diversity of medical task: "Medical Scenario Requirements R A whole-process, whole-scene healthcare refers to health management and disease prevention, diagnosis, control, treatment, as well as rehabilitation. Through exhaustive analysis of the mainstream, more than 40 medical scenarios will be involved….." However, despite referencing an analysis of over 40 medical scenarios, the study only examines two, which does not adequately reflect the complexity and diversity of real-world medical applications. Expanding the evaluation to a broader range of scenarios would strengthen the study's claims regarding the model's applicability and reliability.
[另一个主要问题是所提出框架及其应用缺乏代表性和普遍性。仅评估两个场景不足以证明MedRad模型的稳健性。作者强调了医疗任务的多样性："医疗场景要求R全流程、全场景医疗保健是指健康管理、疾病预防、诊断、控制、治疗以及康复。通过对主流的全面分析，将涉及40多个医疗场景….."然而，尽管引用了40多个医疗场景的分析，但研究只考察了两个，这不足以反映现实世界医疗应用的复杂性和多样性。扩大评估范围到更广泛的场景将加强研究关于模型适用性和可靠性的主张。]

Reviewer 5: The manuscript proposes MedRad, a model designed to enhance clinical decision-making. It proposes a hybrid AI-driven work that improves accuracy and reliability in medical decision support. The study is relevant, and the manuscript is well organized, providing a strong background, a structured methodology, and model evaluation. There are some key areas that require considerations. Please check the attached document for recommendations.
[审稿人5：稿件提出了MedRad，一个旨在增强临床决策的模型。它提出了一个混合AI驱动的工作，提高了医疗决策支持的准确性和可靠性。研究具有相关性，稿件组织良好，提供了强有力的背景、结构化的方法和模型评估。有一些关键领域需要考虑。请查看附件文档中的建议。]

如下是文档：

The manuscript proposes MedRad, a model designed to enhance clinical decision-making. It proposes a hybrid AI-driven work that improves accuracy and reliability in medical decision support.
[稿件提出了MedRad，一个旨在增强临床决策的模型。它提出了一个混合AI驱动的工作，提高了医疗决策支持的准确性和可靠性。]

The study is relevant, and the manuscript is well organized, providing a strong background, a structured methodology, and model evaluation. There are some key areas that require considerations
[研究具有相关性，稿件组织良好，提供了强有力的背景、结构化的方法和模型评估。有一些关键领域需要考虑。]

Introduction and Related Work
[引言和相关工作]

· The study introduces the term "MedRad" but doesn't say what it stands for (an acronym or something else). It should also mention whether it will cover all medical specialties or focus on a specific field.
[研究引入了"MedRad"这个术语，但没有说明它代表什么（是缩写还是其他含义）。它还应该说明是涵盖所有医学专业还是专注于特定领域。]

· Given their structural complexity, particular sentences could need to be reworked for clarity. For instance, the transition from discussing AI's limits to introducing MedRad could have gone more smoothly in the phrase " *In the late of 2022* ". The phrase is a bit uncomfortable and can be changed to " *In late 2022* ."
[考虑到其结构复杂性，某些句子可能需要重新编写以提高清晰度。例如，从讨论AI的限制到引入MedRad的过渡在短语"*In the late of 2022*"中本可以更流畅。这个短语有点不自然，可以改为"*In late 2022*"。]

· The term "higher arithmetic consumption" is ambiguous. Discuss what it is related to, like computational cost, processing power, or efficiency difficulties.
["higher arithmetic consumption"（更高的算术消耗）这个术语模糊不清。讨论它与什么相关，如计算成本、处理能力或效率困难。]

· While the manuscript highlights MedRad's features, it does not clearly outline the research gap it addresses. MedRad is unique compared to current LLM-driven CDSS, yet this aspect is not emphasized enough.
[虽然稿件强调了MedRad的特点，但没有清晰地概述它解决的研究空白。MedRad与当前LLM驱动的CDSS相比是独特的，但这一方面强调得不够。]

Methods
[方法]

· The manuscript fails to name its dataset source and any preprocessing steps to validate data quality. It would be helpful if you provided more details on the contents of the datasets, along with the sources and methods for collecting and curating the data.
[稿件没有说明其数据集来源和任何用于验证数据质量的预处理步骤。如果您能提供关于数据集内容的更多细节，以及收集和整理数据的来源和方法，将会很有帮助。]

Experiment & Results
[实验与结果]

· The manuscript doesn't show or measure the individual impacts of RAG, CoT, and agent-based models. It will be helpful to see how these components contribute to the models accuracy and interpretability.
[稿件没有展示或衡量RAG、CoT和基于代理的模型的单独影响。了解这些组件如何贡献于模型的准确性和可解释性将会很有帮助。]

· The manuscript doesn't contain information on where common failures may occur and their causes.
[稿件没有包含关于常见失败可能发生的位置及其原因的信息。]

· The manuscript does not explicitly discuss medical professionals' interpretations of the model's decision (as it incorporates CoT and RAG). If available, include any positive feedback from medical professionals.
[稿件没有明确讨论医疗专业人员对模型决策的解释（因为它包含了CoT和RAG）。如果有的话，包括医疗专业人员的任何积极反馈。]

· The manuscript does not address how MedRad's performance would apply to international healthcare systems or non-Chinese databases. Talk about whether training MedRad on multilingual data is feasible.
[稿件没有讨论MedRad的性能如何应用于国际医疗系统或非中文数据库。讨论在多语言数据上训练MedRad是否可行。]

· Although AI-driven medical technologies are highly regulated, the manuscript does not address human oversight needs in clinical environments, legal issues (e.g., liability in case of AI-driven misdiagnosis), or regulatory compliance.
[尽管AI驱动的医疗技术受到高度监管，但稿件没有讨论临床环境中的人工监督需求、法律问题（例如，AI驱动误诊的责任）或监管合规性。]

More information and support
[更多信息和支持]

FAQ: How do I revise my submission in Editorial Manager?
[常见问题：如何在Editorial Manager中修改提交？]

[https://service.elsevier.com/app/answers/detail/a_id/28463/supporthub/publishing/](https://service.elsevier.com/app/answers/detail/a_id/28463/supporthub/publishing/ "https://service.elsevier.com/app/answers/detail/a_id/28463/supporthub/publishing/")

You will find information relevant for you as an author on Elsevier's Author Hub: [https://www.elsevier.com/authors](https://www.elsevier.com/authors "https://www.elsevier.com/authors")
[您可以在Elsevier的作者中心找到与您作为作者相关的信息：[https://www.elsevier.com/authors](https://www.elsevier.com/authors "https://www.elsevier.com/authors")]

FAQ: How can I reset a forgotten password?
[常见问题：如何重置忘记的密码？]

[https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/](https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/ "https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/")
For further assistance, please visit our customer service site: [https://service.elsevier.com/app/home/supporthub/publishing/](https://service.elsevier.com/app/home/supporthub/publishing/ "https://service.elsevier.com/app/home/supporthub/publishing/")
Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email
[在这里您可以搜索各种主题的解决方案，找到常见问题的答案，并通过交互式教程了解更多关于Editorial Manager的信息。您还可以通过电话、24/7在线聊天和电子邮件与我们的客户支持团队交谈]

At Elsevier, we want to help all our authors to stay safe when publishing. Please be aware of fraudulent messages requesting money in return for the publication of your paper. If you are publishing open access with Elsevier, bear in mind that we will never request payment before the paper has been accepted. We have prepared some guidelines ([https://www.elsevier.com/connect/authors-update/seven-top-tips-on-stopping-apc-scams](https://www.elsevier.com/connect/authors-update/seven-top-tips-on-stopping-apc-scams "https://www.elsevier.com/connect/authors-update/seven-top-tips-on-stopping-apc-scams") ) that you may find helpful, including a short video on Identifying fake acceptance letters ([https://www.youtube.com/watch?v=o5l8thD9XtE](https://www.youtube.com/watch?v=o5l8thD9XtE "https://www.youtube.com/watch?v=o5l8thD9XtE") ). Please remember that you can contact Elsevier?s Researcher Support team ([https://service.elsevier.com/app/home/supporthub/publishing/)](https://service.elsevier.com/app/home/supporthub/publishing/) "https://service.elsevier.com/app/home/supporthub/publishing/)") at any time if you have questions about your manuscript, and you can log into Editorial Manager to check the status of your manuscript ([https://service.elsevier.com/app/answers/detail/a_id/29155/c/10530/supporthub/publishing/kw/status/).](https://service.elsevier.com/app/answers/detail/a_id/29155/c/10530/supporthub/publishing/kw/status/). "https://service.elsevier.com/app/answers/detail/a_id/29155/c/10530/supporthub/publishing/kw/status/).")
[在Elsevier，我们希望帮助所有作者在发表时保持安全。请注意欺诈性信息，这些信息要求您支付费用以换取论文的发表。如果您通过Elsevier发表开放获取文章，请记住，在论文被接受之前，我们永远不会要求付款。我们准备了一些指南，您可能会觉得有帮助，包括一个关于识别虚假接受信的短视频。请记住，如果您对稿件有任何问题，您可以随时联系Elsevier的研究人员支持团队，您可以登录Editorial Manager查看稿件状态。]
#AU_INFOH#

To ensure this email reaches the intended recipient, please do not delete the above code
[为确保此电子邮件送达预期收件人，请勿删除上述代码]

---

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: [https://www.editorialmanager.com/infoh/login.asp?a=r).](https://www.editorialmanager.com/infoh/login.asp?a=r). "https://www.editorialmanager.com/infoh/login.asp?a=r).") Please contact the publication office if you have any questions.
[根据数据保护法规，您可以随时要求我们删除您的个人注册详细信息。（使用以下URL：[https://www.editorialmanager.com/infoh/login.asp?a=r）。](https://www.editorialmanager.com/infoh/login.asp?a=r)。 "https://www.editorialmanager.com/infoh/login.asp?a=r）。")如果您有任何问题，请联系出版办公室。]
